182 related articles for article (PubMed ID: 35816876)
1. Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
Melo G; Silva CAB; Hague A; Parkinson EK; Rivero ERC
Oral Oncol; 2022 Sep; 132():105979. PubMed ID: 35816876
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
[TBL] [Abstract][Full Text] [Related]
3. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
4. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
5. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.
Carter RJ; Milani M; Butterworth M; Alotibi A; Harper N; Yedida G; Greaves G; Al-Zebeeby A; Jorgensen AL; Schache AG; Risk JM; Shaw RJ; Jones TM; Sacco JJ; Hurlstone A; Cohen GM; Varadarajan S
Cell Death Dis; 2019 Dec; 10(12):912. PubMed ID: 31801952
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects.
Opydo-Chanek M; Gonzalo O; Marzo I
Biochem Pharmacol; 2017 Jul; 136():12-23. PubMed ID: 28288819
[TBL] [Abstract][Full Text] [Related]
7. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract][Full Text] [Related]
8. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
9. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
[TBL] [Abstract][Full Text] [Related]
10. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
11. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
12. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
13. The PPARĪ³ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2.
Li X; He J; Li B; Gao M; Zeng Y; Lian J; Shi C; Huang Y; He F
Mol Carcinog; 2018 Sep; 57(9):1213-1222. PubMed ID: 29856104
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression.
Sumarni U; Zhu J; Sinnberg T; Eberle J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293331
[TBL] [Abstract][Full Text] [Related]
15. BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells.
Graham CD; Kaza N; Pruitt HC; Gibson LM; Klocke BJ; Shevde LA; Carroll SL; Roth KA
Oncotarget; 2017 Jan; 8(5):8670-8678. PubMed ID: 28055968
[TBL] [Abstract][Full Text] [Related]
16. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
17. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
18. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
19. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.
Li R; Boehm AL; Miranda MB; Shangary S; Grandis JR; Johnson DE
Neoplasia; 2007 Oct; 9(10):801-11. PubMed ID: 17971900
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
Biomed Pharmacother; 2024 May; 175():116719. PubMed ID: 38749173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
